Charles Schwab Investment Management Inc. Sells 3,285 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Charles Schwab Investment Management Inc. lowered its holdings in shares of INmune Bio, Inc. (NASDAQ:INMB) by 8.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 33,990 shares of the company’s stock after selling 3,285 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in INmune Bio were worth $183,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in INMB. Financial Advocates Investment Management lifted its stake in shares of INmune Bio by 17.4% in the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock worth $73,000 after purchasing an additional 2,000 shares during the period. Rhumbline Advisers bought a new position in INmune Bio in the second quarter worth approximately $121,000. Fermata Advisors LLC boosted its stake in shares of INmune Bio by 25.2% during the 3rd quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock worth $230,000 after acquiring an additional 8,590 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after acquiring an additional 32,511 shares during the last quarter. Finally, Marshall Wace LLP grew its position in shares of INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after acquiring an additional 89,091 shares during the period. Hedge funds and other institutional investors own 12.72% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on INMB. Alliance Global Partners initiated coverage on INmune Bio in a report on Monday, October 21st. They issued a “buy” rating and a $20.00 target price on the stock. Raymond James assumed coverage on INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Scotiabank started coverage on INmune Bio in a research note on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price objective for the company.

INmune Bio Price Performance

Shares of INMB stock opened at $4.42 on Friday. INmune Bio, Inc. has a one year low of $4.36 and a one year high of $14.74. The company’s fifty day moving average price is $5.28 and its 200-day moving average price is $6.55. The company has a market capitalization of $98.00 million, a price-to-earnings ratio of -2.03 and a beta of 1.79.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same period in the previous year, the business posted ($0.48) earnings per share. Equities research analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other INmune Bio news, CFO David J. Moss purchased 10,000 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were bought at an average cost of $5.29 per share, with a total value of $52,900.00. Following the acquisition, the chief financial officer now owns 1,285,869 shares in the company, valued at approximately $6,802,247.01. This trade represents a 0.78 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 35.20% of the stock is currently owned by company insiders.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.